Katsargyris Athanasios, Hasemaki Natasha, Abu Jiries Melad, Klonaris Chris, Verhoeven Eric L G, Marques de Marino Pablo
Department of Vascular and Endovascular Surgery, General Hospital and Paracelsus Medical University, Nuremberg, Germany; 2nd Department of Vascular Surgery, National and Kapodistrian University of Athens, LAIKO General Hospital of Athens, Athens, Greece.
2nd Department of Vascular Surgery, National and Kapodistrian University of Athens, LAIKO General Hospital of Athens, Athens, Greece.
Eur J Vasc Endovasc Surg. 2025 Mar;69(3):444-451. doi: 10.1016/j.ejvs.2024.10.046. Epub 2024 Nov 6.
The aim of this study was to report outcomes of the BeGraft and BeGraft Plus as bridging covered stents in fenestrated and branched endovascular aneurysm repair (FB-EVAR).
Patients treated and followed in two institutions receiving at least one BeGraft or BeGraft Plus as bridging covered stent between January 2018 and July 2023 were included.
A total of 765 target vessels (TVs) in 281 patients were aimed to be bridged with the BeGraft or BeGraft Plus. Target vessel technical success was 99.5% (761/765). Estimated TV patency at one and two years was 98.5 ± 0.5% and 96.7 ± 0.9%, respectively, with no difference between fenestrations and branches. Estimated freedom from TV related endoleak at one and two years was 98.5 ± 0.5% and 97.9 ± 0.6%, respectively. Estimated freedom from endoleak at two years was lower for TVs targeted with branches compared with TVs targeted with fenestrations (94.2 ± 1.9% vs. 99.7 ± 0.3%, respectively; p < .001). Estimated freedom from TV related re-intervention at one and two years was 97.7 ± 0.6% and 97.1 ± 0.7%, respectively. Estimated freedom from TV related re-intervention at two years was lower for TVs targeted with branches compared with TVs targeted with fenestrations (93.1 ± 2.0% vs. 99.0 ± 0.5%, respectively; p < .001). Estimated freedom from TV instability at one and two years was 96.8 ± 0.7% and 94.5 ± 1.1%, respectively. Estimated freedom from TV instability at two years was 96.0 ± 1.3% for fenestrations and 91.2 ± 2.2% for branches (p = .003).
The BeGraft and BeGraft Plus covered stents showed good midterm outcomes as bridging covered stents in FΒ-EVAR. Branches showed higher instability rates compared with fenestrations. Branches showed similar patency rates to fenestrations.
本研究旨在报告BeGraft和BeGraft Plus作为开窗和分支型血管腔内动脉瘤修复术(FB-EVAR)中的桥接覆膜支架的治疗结果。
纳入2018年1月至2023年7月期间在两家机构接受治疗并随访的患者,这些患者至少接受了一个BeGraft或BeGraft Plus作为桥接覆膜支架。
共有281例患者的765条目标血管(TV)拟用BeGraft或BeGraft Plus进行桥接。目标血管技术成功率为99.5%(761/765)。预计1年和2年时TV通畅率分别为98.5±0.5%和96.7±0.9%,开窗和分支之间无差异。预计1年和2年时TV相关内漏的发生率分别为98.5±0.5%和97.9±0.6%。与开窗目标的TV相比,分支目标的TV在2年时的内漏发生率较低(分别为94.2±1.9%和99.7±0.3%;p<0.001)。预计1年和2年时TV相关再次干预的发生率分别为97.7±0.6%和97.1±0.7%。与开窗目标的TV相比,分支目标的TV在2年时的TV相关再次干预发生率较低(分别为93.1±2.0%和99.0±0.5%;p<0.001)。预计1年和2年时TV不稳定的发生率分别为96.8±0.7%和94.5±1.1%。开窗在2年时TV不稳定的发生率为96.0±1.3%,分支为91.2±2.2%(p = 0.003)。
BeGraft和BeGraft Plus覆膜支架作为FB-EVAR中的桥接覆膜支架显示出良好的中期治疗结果。与开窗相比,分支的不稳定率更高。分支的通畅率与开窗相似。